New weekly shot could help adults with growth hormone deficiency
NCT ID NCT07551804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2a trial tests a new long-acting growth hormone injection called inpegsomatropin in 36 adults with growth hormone deficiency. Participants receive different doses or a placebo once a week to check safety and how well the drug works. The goal is to see if this weekly shot can improve body composition and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inpegsomatropin (a long-acting growth hormone injection)
What this could lead to
If successful, this could provide a once-weekly treatment option for adults with growth hormone deficiency, potentially improving body composition and quality of life.
What could go wrong
This is an early Phase 2a trial with only 36 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Fudan University
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
Beijing, China
Contact
-
The First Affiliated Hospital of Henan University of Science and Technology
Henan, China
Contact
-
The First Affiliated Hospital of Xiamen University
Xiamen, China
Contact
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
Zhejiang, China
Contact
-
West China Hospital, Sichuan University
Sichuan, China
Contact
Contact